Ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate

Art. -Nr.: HY-76558 Reinheit: 99.28%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate is a drug intermediate. Ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate can be used to synthesize inhibitors of various kinases such as Cdk4, PDGF, FGF, EGF.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate Chemische Struktur

CAS. Nr. : 5909-24-0

Größe	Verfügbarkeit	Menge
25 g	Auf Lager	Estimated Time of Arrival: December 31
100 g	Auf Lager	Estimated Time of Arrival: December 31
> 100 g	Angebot einholen

or Massenanfrage

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 1 Customer Validation

Spezialitätsempfehlungen

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biologische Aktivität
Reinheit & Dokumentation
Verweise
Kundenbewertung

Beschreibung	Ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate is a drug intermediate. Ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate can be used to synthesize inhibitors of various kinases such as Cdk4, PDGF, FGF, EGF^[1]^[2].
Molekulargewicht	232.69
Formel	C₈H₉ClN₂O₂S
CAS. Nr.	5909-24-0
Appearance	Solid
Color	White to off-white
SMILES	O=C(OCC)C1=CN=C(SC)N=C1Cl
Versand	Room temperature in continental US; may vary elsewhere.
Speicherung	-20°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Reinheit & Dokumentation	Purity: 99.85% Select Batch: Data Sheet (267 KB) SDS (394 KB) COA (247 KB) HNMR (116 KB) RP-HPLC (241 KB) Handling Instructions (2659 KB)
Verweise	[1]. Barvian M, et al. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16. [Content Brief] [2]. Klutchko SR, et al. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J Med Chem. 1998 Aug 13;41(17):3276-92. [Content Brief]